Ionis Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell IONS and other ETFs, options, and stocks.

About IONS

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T. 

CEO
Brett P. Monia
CEOBrett P. Monia
Employees
1,402
Employees1,402
Headquarters
Carlsbad, California
HeadquartersCarlsbad, California
Founded
1989
Founded1989
Employees
1,402
Employees1,402

IONS Key Statistics

Market cap
12.48B
Market cap12.48B
Price-Earnings ratio
-35.89
Price-Earnings ratio-35.89
Dividend yield
Dividend yield
Average volume
2.14M
Average volume2.14M
High today
$76.00
High today$76.00
Low today
$74.47
Low today$74.47
Open price
$75.26
Open price$75.26
Volume
1.67M
Volume1.67M
52 Week high
$86.74
52 Week high$86.74
52 Week low
$31.66
52 Week low$31.66

Stock Snapshot

Ionis Pharmaceuticals(IONS) stock is priced at $75.45, giving the company a market capitalization of 12.48B. It carries a P/E multiple of -35.89.

As of 2026-05-05, Ionis Pharmaceuticals(IONS) stock has fluctuated between $74.47 and $76.00. The current price stands at $75.45, placing the stock +1.3% above today's low and -0.7% off the high.

Ionis Pharmaceuticals(IONS) shares are trading with a volume of 1.67M, against a daily average of 2.14M.

During the past year, Ionis Pharmaceuticals(IONS) stock moved between $31.66 at its lowest and $86.74 at its peak.

During the past year, Ionis Pharmaceuticals(IONS) stock moved between $31.66 at its lowest and $86.74 at its peak.

IONS News

Simply Wall St 1d
A Look At Ionis Pharmaceuticals Valuation After FDA Priority Review Wins And Upgraded Revenue Guidance

Ionis Pharmaceuticals (IONS) has been in focus after a busy stretch that included US FDA Priority Review and Breakthrough Therapy designations for partner drug...

A Look At Ionis Pharmaceuticals Valuation After FDA Priority Review Wins And Upgraded Revenue Guidance
TipRanks 5d
Ionis Pharmaceuticals price target raised to $86 from $83 at Stifel

Stifel raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $86 from $83 and keeps a Hold rating on the shares. Unlock hedge fund-level data and p...

TipRanks 5d
Ionis Pharmaceuticals’ Earnings Call Flags Growth and Risks

Ionis Pharmaceuticals Inc. ((IONS)) has held its Q1 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks Unlock hedge fund-level d...

Analyst ratings

88%

of 24 ratings
Buy
87.5%
Hold
12.5%
Sell
0%

More IONS News

TipRanks 6d
Analyst Reiterates Buy Rating on Ionis Pharmaceuticals, Maintains $105 Price Target on Strong Q1 and Upgraded Olezarsen Outlook

In a report released today, Joseph Stringer from Needham maintained a Buy rating on Ionis Pharmaceuticals, with a price target of $105.00. Unlock hedge fund-le...

The Motley Fool 6d
Ionis Q1 2026 Earnings Call Transcript

Image source: The Motley Fool. Wednesday, April 29, 2026 at 11:30 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Brett P. Monia Chief Financial Officer —...

Ionis Q1 2026 Earnings Call Transcript
TipRanks 6d
Ionis Pharmaceuticals reports Q1 EPS (56c), consensus (77c)

Reports Q1 revenue $246M, consensus $196.01M. “Ionis’ strong performance in the first quarter of 2026 underscores the strength of our commercial and R&D engines...

Seeking Alpha 7d
GSK granted FDA priority review for Ionis-partnered hep B drug

GSK (GSK) announced on Tuesday that the U.S. Food and Drug Administration (FDA) granted priority review for its marketing application for bepirovirsen, a hepati...

GSK granted FDA priority review for Ionis-partnered hep B drug
TipRanks 7d
Ionis partner GSK announces bepirovirsen NDA accepted for priority review

Ionis Pharmaceuticals (IONS) partner GSK (GSK) announced the FDA has accepted for priority review the new drug application, or NDA, for bepirovirsen, an investi...

People also own

Based on the portfolios of people who own IONS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.